Researchers Team Up To Break Leukemia's Resistance to Treatment with New Compound | GenomeWeb

Researchers at the University of California, San Francisco, and Weill Cornell Medical College in New York City have teamed up to test an investigational drug that could be the key to beating drug resistance in certain forms of leukemia. The drug, called RI-BPI, was developed by Weill Cornell's Ari Melnick, and in a study published in Nature in May, was shown to shut down a transcription factor researchers say is responsible for conferring drug resistance to acute lymphoblastic leukemia.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.